Table 1: Survival time (months) of patients, daily dose of CBD
and prognostic factors.
|
Patient Number° |
Age
at Diagnose (years) |
Survival
since Diagnose (months) |
Genetic
Markups |
Dose
of CBD (mg
/ day) |
|
11 |
31 |
66 (* ?) |
MGMT,
IDH, ATRX, |
560 |
|
5 |
61 |
64 |
MGMT,
1p19q, |
400+ |
|
6 |
41 |
60* |
MGMT, |
400 |
|
1 |
40 |
51 |
n.d. |
400 |
|
3 |
51 |
49* |
MGMT,
IDH, |
600 |
|
15 |
65 |
40* |
MGMT,
IDH, ATRX, |
400 |
|
14 |
56 |
37 |
MGMT, |
400+ |
|
7 |
76 |
28
(median) |
n.d. |
500 |
|
2 |
57 |
21 |
n.d. |
400 |
|
10 |
54 |
14 |
MGMT,
IDH, |
600 |
|
13 |
35 |
14 |
n.d. |
200 |
|
4 |
60 |
13 |
IDH, ATRX, p53, EGFR, |
200 |
|
12 |
49 |
13 |
IDH, ATRX, |
400 |
|
9 |
68 |
8 |
MGMT,
IDH, 1p19q, |
200 |
|
8 |
66 |
7 |
IDH, ATRX, p53, |
200 |
|
Sum
15 |
|
Mean
30.9 months |
|
|
Genetic markups: favourable prognostic factors are,
e.g.: MGMT methylated, IDH mutated, ATRX preserved or p53 preserved, or 1p19
deleted; unfavourable factors are in italics (e.g., unmethylated /
unmutated markers); n.d.: no data;
+ - patient received also THC (7.5mg/day) in addition to CBD; * still
alive;
° numbers refer to the same patients as in the
publication of Likar et al., (2021) [9].